Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02WLS
|
|||
| Former ID |
DIB005431
|
|||
| Drug Name |
Onyvax-105
|
|||
| Synonyms |
Antibody therapy (colerectal cancer), CRC/Onyvax; Vaccine (colorectal cancer), CRC/ImClone; Vaccine (colorectal cancer), CRC/Onyvax
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 1/2 | [1] | |
| Colorectal cancer [ICD-11: 2B91.Z] | Discontinued in Phase 1 | [2] | ||
| Company |
Cancer Research Campaign; VaxOnco
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement decay-accelerating factor (CD55) | Target Info | . | [3] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Hematopoietic cell lineage | ||||
| Viral myocarditis | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| FSH Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Class B/2 (Secretin family receptors) | |||
| Regulation of Complement cascade | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Complement Activation, Classical Pathway | ||||
| Human Complement System | ||||
| GPCR ligand binding | ||||
| Complement cascade | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Onyvax-105 Cancer Vaccine Shows Encouraging Clinical Results in Osteosarcoma Patients After Intensive Chemotherapy. Onyvax vaccines therapies. April 19, 2005. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006889) | |||
| REF 3 | Technology evaluation: Onyvax-105, Onyvax. Curr Opin Mol Ther. 2003 Dec;5(6):668-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.